Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bupivacaine in Unilateral Mastectomy Without Reconstruction
NCT03351348Phase 3Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2017
- Primary completion
- Nov 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bupivacaine in postoperative pain (2 arms), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Number of patients that have moderate to severe pain at 24 hours. Started Nov 2017; status: active, not recruiting.
02
Drugs
bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT03351348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03351348.